Compare Stanley Black & Decker, Inc. (SWK) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stanley Black & Decker, Inc. vs GeneDx Holdings Corp — how do they compare? Stanley Black & Decker, Inc. trades at $91.6 (market cap $13.85B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.58B). The key difference: Stanley Black & Decker, Inc. is far larger — about 5.4× GeneDx Holdings Corp's market cap, and Stanley Black & Decker, Inc. pays a 3.66% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| SWK | WGS | |
|---|---|---|
Market Cap | $13.85B | $2.58B |
52-Week High | $104.00 | $167.51 |
52-Week Low | $62.12 | $34.51 |
Enterprise Value | $18.01B | $2.61B |
Dividend Yield | 3.66% | — |
Sector | — | Technology |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stanley Black & Decker (SWK) trades at $93.81, down 3.65% on the day, with a bearish technical signal from moving averages and oscillators. The company reported three consecutive quarterly earnings beats, with Q3 2026 results pending. Recent portfolio refinement includes the sale of Excel Industries to Bad Boy Mowers. Valuation metrics show a P/E of 22.94 and P/S of 0.93, with a net income margin of 4.07% for 2025.
The outlook is mixed: analyst consensus is a $98.50 price target with 43% buy ratings, but technical indicators suggest near-term pressure. Opportunities include cost transformation benefits and dividend stability, while risks involve debt levels and industrial demand volatility. The stock's current price is near the low end of analyst targets, indicating potential upside if fundamentals strengthen.
WGS trades at $85.87, down 0.14% on the day, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4 million, beating estimates, and achieved adjusted profitability ahead of schedule. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics, driving positive sentiment.
Outlook is cautiously optimistic due to strong analyst support (90.9% buy ratings) and revenue growth, but risks include negative net income margins, high valuation multiples, and ongoing class action lawsuits. The stock's upside potential hinges on sustained operational improvements and market expansion in genomics diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
